Syneron receives US FDA clearance to market UltraShape for fat cell destruction
Syneron Medical Ltd. (NASDAQ: ELOS) has announced that it has received the United States Food and Drug Administration (FDA) 510(k) clearance to market the UltraShape™ System for non-invasive reduction of abdominal circumference...
Read More
